Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review

Abstract Background Foetal bovine serum (FBS), is the most commonly used culture medium additive for in vitro cultures, despite its undefined composition, its potential immunogenicity and possible prion/zoonotic transmission. For these reasons, significant efforts have been targeted at finding a sub...

Full description

Bibliographic Details
Main Authors: M. Guiotto, W. Raffoul, A. M. Hart, M. O. Riehle, P. G. di Summa
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Journal of Translational Medicine
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12967-020-02489-4
_version_ 1828543643047165952
author M. Guiotto
W. Raffoul
A. M. Hart
M. O. Riehle
P. G. di Summa
author_facet M. Guiotto
W. Raffoul
A. M. Hart
M. O. Riehle
P. G. di Summa
author_sort M. Guiotto
collection DOAJ
description Abstract Background Foetal bovine serum (FBS), is the most commonly used culture medium additive for in vitro cultures, despite its undefined composition, its potential immunogenicity and possible prion/zoonotic transmission. For these reasons, significant efforts have been targeted at finding a substitute, such as serum free-media or human platelet-lysates (hPL). Our aim is to critically appraise the state-of-art for hPL in the published literature, comparing its impact with FBS. Materials and methods In June 2019 a systematic search of the entire Web of Science, Medline and PubMed database was performed with the following search terms: (mesenchymal stem cells) AND (fetal bovine serum OR fetal bovine calf) AND (human platelet lysate). Excluded from this search were review articles that were published before 2005, manuscripts in which mesenchymal stem cells (MSCs) were not from human sources, and when the FBS controls were missing. Results Based on our search algorithm, 56 papers were selected. A review of these papers indicated that hMSCs cultured with hPL showed a spindle-shaped elongated morphology, had higher proliferation indexes, similar cluster of differentiation (CD) markers and no significant variation in differentiation lineage (osteocyte, adipocyte, and chondrocyte) compared to those cultured with FBS. Main sources of primary hMSCs were either fat tissue or bone marrow; in a few studies cells isolated from alternative sources showed no relevant difference in their response. Conclusion Despite the difference in medium choice and a lack of standardization of hPL manufacturing, the majority of publications support that hPL was at least as effective as FBS in promoting adhesion, survival and proliferation of hMSCs. We conclude that hPL should be considered a viable alternative to FBS in hMSCs culture—especially with a view for their clinical use.
first_indexed 2024-12-12T02:17:36Z
format Article
id doaj.art-01537c897452463c9405434865d09a9a
institution Directory Open Access Journal
issn 1479-5876
language English
last_indexed 2024-12-12T02:17:36Z
publishDate 2020-09-01
publisher BMC
record_format Article
series Journal of Translational Medicine
spelling doaj.art-01537c897452463c9405434865d09a9a2022-12-22T00:41:46ZengBMCJournal of Translational Medicine1479-58762020-09-0118111410.1186/s12967-020-02489-4Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic reviewM. Guiotto0W. Raffoul1A. M. Hart2M. O. Riehle3P. G. di Summa4Department of Plastic, Reconstructive and Hand Surgery, Centre Hospitalier Universitaire Vaudois (CHUV)Department of Plastic, Reconstructive and Hand Surgery, Centre Hospitalier Universitaire Vaudois (CHUV)Centre for the Cellular Microenvironment, University of GlasgowCentre for the Cellular Microenvironment, University of GlasgowDepartment of Plastic, Reconstructive and Hand Surgery, Centre Hospitalier Universitaire Vaudois (CHUV)Abstract Background Foetal bovine serum (FBS), is the most commonly used culture medium additive for in vitro cultures, despite its undefined composition, its potential immunogenicity and possible prion/zoonotic transmission. For these reasons, significant efforts have been targeted at finding a substitute, such as serum free-media or human platelet-lysates (hPL). Our aim is to critically appraise the state-of-art for hPL in the published literature, comparing its impact with FBS. Materials and methods In June 2019 a systematic search of the entire Web of Science, Medline and PubMed database was performed with the following search terms: (mesenchymal stem cells) AND (fetal bovine serum OR fetal bovine calf) AND (human platelet lysate). Excluded from this search were review articles that were published before 2005, manuscripts in which mesenchymal stem cells (MSCs) were not from human sources, and when the FBS controls were missing. Results Based on our search algorithm, 56 papers were selected. A review of these papers indicated that hMSCs cultured with hPL showed a spindle-shaped elongated morphology, had higher proliferation indexes, similar cluster of differentiation (CD) markers and no significant variation in differentiation lineage (osteocyte, adipocyte, and chondrocyte) compared to those cultured with FBS. Main sources of primary hMSCs were either fat tissue or bone marrow; in a few studies cells isolated from alternative sources showed no relevant difference in their response. Conclusion Despite the difference in medium choice and a lack of standardization of hPL manufacturing, the majority of publications support that hPL was at least as effective as FBS in promoting adhesion, survival and proliferation of hMSCs. We conclude that hPL should be considered a viable alternative to FBS in hMSCs culture—especially with a view for their clinical use.http://link.springer.com/article/10.1186/s12967-020-02489-4Human platelet lysateFoetal bovine serumMesenchymal stem cellsAdipose derived stem cellsCell therapy
spellingShingle M. Guiotto
W. Raffoul
A. M. Hart
M. O. Riehle
P. G. di Summa
Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review
Journal of Translational Medicine
Human platelet lysate
Foetal bovine serum
Mesenchymal stem cells
Adipose derived stem cells
Cell therapy
title Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review
title_full Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review
title_fullStr Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review
title_full_unstemmed Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review
title_short Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review
title_sort human platelet lysate to substitute fetal bovine serum in hmsc expansion for translational applications a systematic review
topic Human platelet lysate
Foetal bovine serum
Mesenchymal stem cells
Adipose derived stem cells
Cell therapy
url http://link.springer.com/article/10.1186/s12967-020-02489-4
work_keys_str_mv AT mguiotto humanplateletlysatetosubstitutefetalbovineseruminhmscexpansionfortranslationalapplicationsasystematicreview
AT wraffoul humanplateletlysatetosubstitutefetalbovineseruminhmscexpansionfortranslationalapplicationsasystematicreview
AT amhart humanplateletlysatetosubstitutefetalbovineseruminhmscexpansionfortranslationalapplicationsasystematicreview
AT moriehle humanplateletlysatetosubstitutefetalbovineseruminhmscexpansionfortranslationalapplicationsasystematicreview
AT pgdisumma humanplateletlysatetosubstitutefetalbovineseruminhmscexpansionfortranslationalapplicationsasystematicreview